Deutsch English Français

Contact

EP0560967

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP0560967

EP0560967 - USE OF AICA RIBOSIDE COMPOUNDS FOR THE TREATMENT AND PREVENTION OF TISSUE DAMAGE DUE TO DECREASED BLOOD FLOW [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 29.11.1996 Database last updated on 14.09.2024
Most recent event Tooltip	29.11.1996	Application deemed to be withdrawn	published on 15.01.1997 [1997/03]
Applicant(s)	For all designated states GENSIA, INC. 9360 Towne Centre Drive San Diego, CA 92121 / US
	[1995/26]
Former [1993/38]	For all designated states GENSIA PHARMACEUTICALS, INC. 11025 Roselle Street San Diego, CA 92121 / US
Inventor(s)	01 / GRUBER, Harry, Edward 13083 Maritime Place San Diego, CA 92130 / US
	02 / MULLANE, Kevin, Michael 13814 Boquita Drive Del Mar, CA 92014 / US
	03 / LAIKIND, Paul, Kevin 3370 Goldfinch Street San Diego, CA 92013 / US
	[1993/38]
Representative(s)	Sexton, Jane Helen, et al J A Kemp 14 South Square Gray's Inn London WC1R 5JJ / GB
	[N/P]
Former [1993/38]	Sexton, Jane Helen, et al J.A. KEMP & CO. 14 South Square Gray's Inn London WC1R 5LX / GB
Application number, filing date	92921355.1	28.09.1992
	[1993/38]
	WO1992US08304
Priority number, date	US19910770023	30.09.1991 Original published format: US 770023
	[1993/38]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO9306833
	Date:	15.04.1993
	Language:	EN
	[1993/10]
	Type:	A1 Application with search report
	No.:	EP0560967
	Date:	22.09.1993
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 15.04.1993 takes the place of the publication of the European patent application.
	[1993/38]
Search report(s)	International search report - published on:	EP	15.04.1993
Classification	IPC:	A61K31/70	[1993/38]
	CPC:	A61K31/70 (EP,US); A61P9/00 (EP); Y10S435/975 (EP,US)
	C-Set:	A61K31/70, A61K2300/00 (US,EP); A61K31/70, A61K31/52 (EP,US)
Designated contracting states	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE [1995/07]
Former [1993/38]	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, SE
Title	German:	VERWENDUNG VON AICA-RIBOSID VERBINDUNGEN ZUR BEHANDLUNG UND VORBEUGUNG DER DURCH VERMINDERTE BLUTSTRÖMUNG VERURSACHTEN GEWEBESCHÄDEN	[1993/38]
	English:	USE OF AICA RIBOSIDE COMPOUNDS FOR THE TREATMENT AND PREVENTION OF TISSUE DAMAGE DUE TO DECREASED BLOOD FLOW	[1993/38]
	French:	UTILISATION DE COMPOSES DE AICA RIBOSIDES POUR LE TRAITEMENT ET LA PREVENTION DE DOMMAGES DE TISSUS DUS A UNE DIMINUTION DE L'ECOULEMENT SANGUIN	[1993/38]
File destroyed:	20.04.2002
Miscellaneous	EPB 1995/08: Verbunden mit 92308801.7/0535884 (europäische Anmeldenummer/Veröffentlichungsnummer) durch Entscheidung vom 05.01.95
	EPB 1995/08: Consolidated with 92308801.7/0535884 (European application no./publication no.) by decision dated 05.01.95
	EPB 1995/08: Jointe à la demande no. 92308801.7/0535884 (numéro de dépôt/numéro de publication de la demande européenne) par décision du 05.01.95
Entry into regional phase	27.05.1993	National basic fee paid
	27.05.1993	Designation fee(s) paid
	27.05.1993	Examination fee paid
Examination procedure	27.05.1993	Examination requested [1993/38]
	08.01.1996	Despatch of a communication from the examining division (Time limit: M06)
	20.05.1996	Application deemed to be withdrawn, date of legal effect [1997/03]
	19.08.1996	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [1997/03]
Fees paid	Renewal fee
	12.09.1994	Renewal fee patent year 03
	06.09.1995	Renewal fee patent year 04
	Penalty fee
	Additional fee for renewal fee
	30.09.1996	05 M06 Not yet paid
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited in	International search	[X]US4575498 (HOLMES EDWARD W [US], et al);
		[X]WO8705807 (GRUBER HARRY EDWARD);
		[X]WO9009163 (GENSIA PHARMA [US]);
		[XP]WO9202213 (GENSIA PHARMA [US]);
		[XP]WO9202214 (GENSIA PHARMA [US])
		[XP] - Supplement to the Journal of the American College of Cardiology, vol. 19, no. 3, supplement A, 1 March 1992, J. LEUNG et al.: "Effects of acadesine on perioperative cardiac morbidity in a placebo controlled, double blind study", page 112A, see the whole document
		[A] - Circulation, vol. 80, no. 5, November 1989, H.E. GRUBER et al.: "Increased adenosine concentration in blood from ischemic myocardium by AICA riboside", pages 1400-1411, see abstract
		[XP] - Circulation, vol. 86, no. 2, August 1992, M. GALINANES et al.: "Acadesine and myocardial protection. Studies of time of administration and dose-response relations in the rat", pages 598-608, see abstract
		[X] - Annals of Plastic Surgery, vol. 26, no. 6, June 1991, Little, Brown and Co., G.M. SALERNO et al.: "The use of 5-aminoimidazole-4-carboxamide riboside (AICA riboside) to improve random skin flap viability in the rat model", pages 544-550, see abstract

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p